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Fig. 1. Multivariate model converted to a graphic nomogram for prediction of progression free survival. Each variable in the model, corresponding to the characteris
individual patient, is assigned to an individual score. A probability for progression free survival can be calculated by drawing a vertical line from each predictor val
score scale at the top—‘points’. After manually summing up the scores, the ‘total points’ correspond to the probability of progression free survival, which are estim
drawing a vertical line from this value to the bottom scales to estimate overall survival. Smoking was categorized as none, moderate (1–30 pack years of smoking) a
(>30 pack years of smoking).Emmanuel Rios Velazquez a, Frank Hoebers a,⇑, Hugo J.W.L. Aerts b, Michelle M. Rietbergen c,
Ruud H. Brakenhoff c, René C. Leemans c, Ernst-Jan Speel d, Jos Straetmans e, Bernd Kremer e,
Philippe Lambin a
aDepartment of Radiation Oncology (MAASTRO), Research Institute GROW, Maastricht University, Maastricht, The Netherlands; bDepartment of Radiation Oncology, Dana-Farber
Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA; cDepartment of Otolaryngology – Head and Neck Surgery, VU University Medical Center,
Amsterdam; dDepartment of Pathology, Maastricht University Medical Centre+; and eDepartment of Otolaryngology – Head and Neck Surgery, Maastricht University Medical Centre+,
The NetherlandsThe authors sincerely apologize for an incorrectness in Fig. 1.
This was drawn to their attention by a guest user of the website
www.predictcancer.org where the variables in the model derived
from the paper can be used interactively.
The labels for the clinical T-Stage variable were incorrectly
ordered as T1, T2, T3, T4. The correct order should be T1, T2, T4and T3. In addition, the endpoint in Fig. 1 refers to Progression Free
Survival. The corrected Fig. 1 and corrected legend are presented
below.
The authors do not think this mistake affects the results and
conclusions of the paper, because the HRs in Table 2 of the original
article already indicated higher values for T3 compared to T4tics of an
ue to the
ated by
nd heavy
338 Erratum / Radiotherapy and Oncology 124 (2017) 337–338tumor. At first glance this appears counterintuitive, however in
previous studies [1] it was also demonstrated that higher T-stage
was not associated with worse outcome after chemoradiation,
because the most prominent factor appeared to be tumor volume.
In this respect, a small tumor with bone invasion (i.e. T4) might
respond more favourably to radiation, compared to a more volumi-
nous T3 tumor without bone invasion.Reference
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